Simple Summary Chronic myeloid leukemia (CML) is a myeloproliferative neoplasia
associated with a molecular alteration, the fusion gene BCR-ABL1, that encodes the tyrosine …

Chronic myeloid leukemia (CML) is driven by the BCR-ABL1 fusion protein, formed by a
translocation between chromosomes 9 and 22 that creates the Philadelphia chromosome …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Background In cancer research, high-throughput screening technologies produce large
amounts of multiomics data from different populations and cell types. However, analysis of …

Chronic myeloid leukemia (CML) is a clonal myeloproliferative neoplasm driven by BCR-
ABL1 oncoprotein, which plays a pivotal role in CML pathology, diagnosis, and treatment as …

Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm and was the first
neoplastic disease associated with a well-defined genotypic anomaly―the presence of the …

The topological indices provide quantitative structural characteristics of drug molecules that
can be utilized to predict or establish correlations with the biological activity …

Tyrosine kinase inhibitors (TKIs) exemplify the success of molecular targeted therapy for
chronic myeloid leukemia (CML). However, some patients do not respond to TKI therapy …

The unfolded protein response (UPR) is an evolutionarily conserved adaptive signaling
pathway triggered by a stress of the endoplasmic reticulum (ER) lumen compartment, which …

Asciminib (Scemblix) is a first‐in‐class BCR:: ABL1 inhibitor that works by specifically
targeting the ABL myristoyl pocket (STAMP) and has potent activity against the T315I …